Patients eligible for , or receiving , step 3 or step 4 combination therapy per National Heart , Lung , and Blood Institute guidelines , received ICS plus either once-daily tiotropium ( n = 532 ) or twice-daily LABAs ( n = 538 , ) and were followed up for up to 18 months .